Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients.
CONCLUSION: Newer antidiabetic agents have been recommended by the American Diabetes Association for potential cardiovascular, renal, and hypoglycemic benefits. Particular agents, such as DPP-4 inhibitors and GLP-1 RAs may play a role in correcting PTDM-related defects. Clinicians need to take into account both patient-specific and drug-specific characteristics when initiating these agents in KTRs.
PMID: 32795145 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Anderson S, Cotiguala L, Tischer S, Park JM, McMurry K Tags: Ann Pharmacother Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Fortamet | Heart | Kidney Transplant | Kidney Transplantation | Metformin | SGLT2 Inhibitors | Sodium | Study | Transplant Surgery | Transplants | Urinary Tract Infections | Urology & Nephrology